New radioactive drug targets Hard-to-Treat tumors in early trial
NCT ID NCT06184035
First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This study is testing an experimental radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The drug is designed to deliver radiation directly to tumors. The main goals are to find the safest dose and to see if it can shrink tumors or slow their growth. About 90 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research South Adelaide
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact
-
St Vincent Hospital Melbourne
RECRUITINGMelbourne, Victoria, 3065, Australia
Contact
Conditions
Explore the condition pages connected to this study.